CVTX up on CVT-3146 news

CV Therapeutics (CVTX) was up $2.83 (14%) to $22.74 on Monday. The company said it plans to start ahead of schedule Phase III testing next year of its CVT-3146 as a pharmacologic stress agent for use ...